Solvonis Therapeutics plc (LSE:SVNS) has successfully synthesized development candidates for its SVN-SDN-014 initiative, aimed at pioneering a novel class of treatments for post-traumatic stress disorder (PTSD). This accomplishment represents the third phase in the company’s seven-step translational development strategy, which is designed to improve therapeutic safety and foster pro-social behavior among PTSD patients. The milestone reflects Solvonis’s continued drive to meet critical mental health challenges. Upcoming stages in the development process will involve in-vitro assays and pre-clinical trials in animal models, bringing the program closer to potential regulatory submission.
About Solvonis Therapeutics
Headquartered in London, Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company committed to developing innovative therapies for addiction and mental health conditions. Traded on the London Stock Exchange, the company focuses on treating complex neuropsychiatric disorders such as Post-Traumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD). Leveraging a cost-effective model and a dual development approach, Solvonis is advancing both repurposed and proprietary drug candidates to address pressing unmet needs in mental health care.
Leave a Reply